These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29387553)

  • 21. Deep reinforcement learning identifies personalized intermittent androgen deprivation therapy for prostate cancer.
    Lu Y; Chu Q; Li Z; Wang M; Gatenby R; Zhang Q
    Brief Bioinform; 2024 Jan; 25(2):. PubMed ID: 38493345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?
    Klotz L; Toren P
    Curr Oncol; 2012 Dec; 19(Suppl 3):S13-21. PubMed ID: 23355789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy.
    Pascal LE; Masoodi KZ; O'Malley KJ; Shevrin D; Gingrich JR; Parikh RA; Wang Z
    J Urol; 2015 Apr; 193(4):1388-93. PubMed ID: 25444984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
    Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F
    Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial.
    Yokomizo A; Koga H; Ito K; Takezawa Y; Komiyama M; Nishimura K; Yonese J; Hashine K; Masumori N; Arai G; Saito S; Shinohara M; Shimizu N; Yamauchi A; Satoh T; Tochigi T; Kobayashi M; Fujimoto H; Kakimoto KI; Fukui I; Tsukamoto T; Nozaki M; Karasawa K; Hasumi M; Ohtani M; Ishiyama H; Kuwahara M; Harada M; Ohashi Y; Kotake T; Kakizoe T; Suzuki K; Naito S; Yamanaka H;
    Cancer Med; 2021 May; 10(10):3240-3248. PubMed ID: 33932114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy.
    Abrahamsson PA; Boccon-Gibod L; Morote J; de Jong IJ; Malmberg A; Neijber A; Albers P
    Eur Urol Focus; 2017 Oct; 3(4-5):470-479. PubMed ID: 28753747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models.
    Masoodi KZ; Ramos Garcia R; Pascal LE; Wang Y; Ma HM; O'Malley K; Eisermann K; Shevrin DH; Nguyen HM; Vessella RL; Nelson JB; Parikh RA; Wang Z
    Endocrinology; 2013 Jul; 154(7):2296-307. PubMed ID: 23671262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.
    Gupta S; Wang Y; Ramos-Garcia R; Shevrin D; Nelson JB; Wang Z
    Prostate; 2010 Oct; 70(14):1575-85. PubMed ID: 20564326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer.
    Salonen AJ; Taari K; Ala-Opas M; Viitanen J; Lundstedt S; Tammela TL;
    J Urol; 2012 Jun; 187(6):2074-81. PubMed ID: 22498230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Intermittent and Continuous Androgen Deprivation Therapy in Prostate Cancer Patients: An Up-to-Date Meta-analysis for Urologists and Medical Providers.
    Becker B; Stroever S; Reddy A; de Riese WTW
    Urol Pract; 2023 Sep; 10(5):424-434. PubMed ID: 37505912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intermittent androgen deprivation therapy in advanced prostate cancer.
    Alva A; Hussain M
    Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study.
    Tsai HT; Pfeiffer RM; Philips GK; Barac A; Fu AZ; Penson DF; Zhou Y; Potosky AL
    J Urol; 2017 May; 197(5):1251-1257. PubMed ID: 27993663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and tolerability of intermittent androgen deprivation therapy: a literature review.
    Gruca D; Bacher P; Tunn U
    Int J Urol; 2012 Jul; 19(7):614-25. PubMed ID: 22435512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intermittent complete androgen blockade in metastatic prostate cancer.
    Rambeaud JJ
    Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).
    Schulman C; Cornel E; Matveev V; Tammela TL; Schraml J; Bensadoun H; Warnack W; Persad R; Salagierski M; Gómez Veiga F; Baskin-Bey E; López B; Tombal B
    Eur Urol; 2016 Apr; 69(4):720-727. PubMed ID: 26520703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.
    Abrahamsson PA
    Eur Urol; 2010 Jan; 57(1):49-59. PubMed ID: 19683858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefits of intermittent/continuous androgen deprivation in patients with advanced prostate cancer.
    Muresanu H
    Clujul Med; 2016; 89(3):419-22. PubMed ID: 27547063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intermittent Complete Androgen Blockade in Metastatic Prostate Cancer.
    Rambeaud J
    Eur Urol; 1998 Dec; 35 Suppl S1():32-36. PubMed ID: 9858850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
    J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.